#### Back to the Basics: Axillary Staging in Breast Cancer


8:30 – 9:15 Friday, November 24, 2006


Dr. N. Davis Surgical Oncology Network BCCA Annual Conference


# Objectives


- To review Axillary Staging in Breast Cancer
- To review issues related to axillary sentinel lymph node biopsy
- To review indications and outcomes related to standard Axillary Node Dissection for Breast Cancer
- To propose quality indicators for lymph node dissection

DC Gencer Agency











# Risk of axillary recurrence NSABP trial B-04 - clinically negative 0 nodes removed - 28 % recurrence 6 nodes removed - 0 6 nodes removed - 0 0.3% in node negative patients Int J Rad Oncol Biol Phys 1993;26:593-9 2.1% in node positive (< 4) patients J Clin Oncol 1991;9:988-96

Study	N	Follow-up (Years)	Treatment	Axillary Recurrence	Uncontrolled Disease in Axilla
NSABP B-04 Fisher, NEJM 1985;312:674-81.	365		SM	17.8%	1.1%
CRC Houghton, WJ Surg 1994;18: 117-22.	1424	20	SM	19.5%	6.3%

	illary failure n f/u = 62 moi						
Table 2. AXILLARY NODAL RELAPSES AND DISTANT METASTASIS IN PATIENTS GROUPED ACCORDING TO TUMOR SIZE							
Patient Subgroup	Events	No. of Events/Total Cases	%				
T1a	Nodal relapses Distant metastases	2/102 6/102	2.0				
T1b	Nodal relapses Distant metastases	2/114 3/111	1.7				
T1c	Nodal relapses Distant metastases	15/143 22/143	10.8 15.4				
T2	Nodal relapses Distant metastases	7/38 13/38	18.4				





# Question

Should patients undergo formal Axillary Node Dissection or is Sentinel Node biopsy the standard of care for axillary sampling?

## What is accepted

- SNB accurately stages the axilla
- It has less morbidity than axillary node dissection
- Modern techniques have made it technically easier

#### DC Gancer Agency

#### C Gancer Agency

### SLNBx

- ≻ High False negative rate (10%)
- Similar complications to ALNDx
- Impact on Survival and Local-Regional recurrence unknown
- Tends to detect micrometastatic disease for which the surgical management remains controversial

#### BC Cancer Agency

# Contra-indications for SLNB

- ✓ Absence of experienced surgeon + team
- ✓ DCIS (BCS)
- ✓ Prophylactic mastectomy
- Multifocal tumours
- Locally advanced cancer
  - Inflammatory
- > Clinically palpable nodes
- BC, Cancer Agency

- Previous breast/axillary surgery/radiation
- Pre-op chemotherapy
- > Pregnancy
- ✓ Breast feeding
- ✓ Allergies
- ✓ True contra-indications

Relative contra-indication

### What is debatable

- ≻Is SLNBx accurate enough?
- Does it compromise regional control?
- ≻Does it lower DFS and OS?

#### BL Cancer Agency

# What is Confusing

- ➤Using National Guidelines, ALNDx is still considered the "gold standard" of care in Canada
  - No evidence that SLNBx is equivalent with respect to survival and local recurrence
- Associated with lower quality of life scores than Sentinel Node Biopsy

# Canadian Guidelines: AND

Removal and pathological examination of axillary lymph nodes should be standard procedure for patients with early, invasive breast cancer.

Omission of axillary dissection may be considered when the risk of axillary metastasis is very low or when knowledge of node status will have no influence on therapy.

The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer, CMAJ, 1998 Feb 10;158 Suppl 3:S22-6.

	Reserve	Clinical practice guidelines care and treatment of breast 13. Sentinel lymph node bio
	Roberthe	
Concorr Agency	14. Characteristic and Automation Processing and Automation and Automatical Automation of Automatical Automatic	<ul> <li>Anger Carlin, Hagh Karth, Mald Livik, Marki Karth, Karth Carlin, Canadhar et Chand Mark Karth Carling Canadhar and Shark Shar</li></ul>
		tade of Association at the Research

# for the st cancer: opsy

# Practice Guidelines in Diroclegy - v.2.2006 Invasive Breast Cancer INC. STATE ( IN AND IN A or core

Non Altern

# Canadian Guidelines: SLNB

Axillary dissection is the standard of care for the surgical staging of operable breast cancer.

If a patient requests or is offered SLN biopsy, the benefits and risks as well as what is and is not known about the procedure should be outlined.

The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. CMAJ 2001;165(2):166-73

**Cancer Care Ontario Guidelines** 

Removal and pathological examination of levels I and II axillary lymph nodes should be the stan-

dard practice in most cases of

185

stages I and II breast carcinoma.

🛞 Can J Surg, Vol. 48, No. 3, June 2005

# **ASCO** Guidelines

Conclusion SNB is an appropriate initial alternative to routine staging ALND for patients with early-stage breast cancer with clinically negative axillary nodes. Completion ALND remains standard treatment for patients with axillary metastases identified on SNB. Appropriately identified patients with negative results of SNB, when done under the direction of an experienced surgeon, need not have completion ALND. Isolated cancer cells detected by pathologic examination of the SLN with use of specialized techniques are currently of unknown clinical significance. Although such specialized techniques are often used, they are not a required part of SLN evaluation for breast cancer at this time. Data suggest that SNB is associated with less motbidity than ALND, but the comparative effects of these two approaches on tumor recurrence or patient survival are unknown. tumor recurrence or patient survival are unknown

J Clin Oncol 23:7703-7720. © 2005 by American Society of Clinical Oncology

# Question

Should patients undergo formal Axillary Node Dissection or is Sentinel Node biopsy the standard of care for axillary sampling?

# To Clarify:

- > Do we be concerned about the False Negative rate?
- Does stand alone SLNBx compromise local recurrence rates?
- Does stand alone SLNBx compromise survival?
- ≻Can we monitor quality of surgery?

#### DC Concer Agency

	F	NR (	)f SL	NBx		
Author	Year	Patients	Agent	SLN Id	FN Rate	Accuracy
		#		%	%	%
Krag	1998	443	IPC	91	11	97
Tafra	2001	535	IPC, IPD	87	13	96
Shivers	2002	426	Varied	86	4	99
McMaster	2003	3975	Varied	94	8	96
Chua (BC)	2003	547	Varied	88	22	92
Krag	2004	2461	IPC, IPD	97	10	97
Goyal	2006	836	IPC, IPD	96	7	98

	Μ	lisund	lersta	nding	g??
		A	۱D		
				Total	FNR=10.7%
		650		650	PPV=100%
		70	1741	1811	NPV=96%
	Total	720	1741	2461	
C Concer Ag	Sensitivi et al, San Ant		Specifici	ty=100%	

# Negative Predictive Value

- >96% NPV = 4/100 women incorrectly diagnosed or @1/25
- ➤ 10% FNR implies 1/10 women misdiagnosed which is not the case if the entire cohort is considered

#### Df. Cancer Agency per corpore

DC Cancer Agency

# FN rate of Axillary Node Dissection

Author	Year	N (node negative)	# with occult mets	
Reed	2004	385	45	12% (@32% FN rate)
Ludwig group	1990	921	83	9%
Millis	2001	477	60	13 % FN rate 33%
Cote	1999	736	148	20%
Nasser	1993	159	50	11%

# False negative rate of ALND is similar to the FNR of SLNBx.

Should ALND be considered the "Gold Standard" for axillary sampling?

DC Cancer Agency

#### Loco-regional recurrences following SLNBx

#### ≻N = 149

- F/u = 65 months (mean)
- ≻4 patients had an axillary recurrence at 10, 12, 14, and 56 months (2.7%)
- ➤ 3 patients free of disease
- > One died from systemic disease but no regional recurrence

De Kanter et al: EJSO 32, 2006

# Prospective Study SNB vs. Routine AND >N = 516 > <= 2 cm tumors</td> > Patients randomized to SNB or routine AND > Intra-operative frozen sections > Median follow-up 46 mos

Veronesi et al NEJM – 349: 546, 2003

 AND
 SNB

 Recurrence
 Axilla
 0
 0

 Axilla
 0
 0

 Supraclavicular
 2
 0

 Breast
 1
 1

 Contralateral breast
 2
 3

 Distant
 10
 6

 Death
 1
 1

 Other
 4
 1


 Other
 4
 1

 \* Median follow-up = 46 months
 1

Outcome AND vs. SNB

# AND compared to SNB: Side Effects (24 mos)


Mobility	AND (n=100)	SN (n=100)	
80-100 %	79	100	
Swelling (circumfe	rence)		
No difference	25		
< 1 cm	38		
1 – 2 cm	25		
> 2 cm	12		
	Veronesi et al NEJM -	- 349: 546, 2003	
BL Cancer Agency			



### Complications of Axillary Surgery

#### Dr. Rona Cheifetz

CAGS/CSSO & BC SON National Advisory Panel on Management of the Axilla Kelowna September 29, 2006



# **Best Evidence**

#### > ALMANAC Trial 2006 JNCI 98(9)

- Randomized, intention to treat analysis
- 495 SLNB vs 496 'standard' treatment
- Terminated early after ethical review (initial was for 610 per group)
- All validated SLNB with 40 cases first
- + SLNB offered either XRT or CLND
- 12 month follow-up data reported

]	in	ni	ta	ti	0	n	S	i	n	t	he	)	E	v	i	e	n	C	e

- ≻Few prospective randomized trials
- Measurement tools differ btw studies
- ≻Short follow-up
- ► Apples and Oranges
  - Axillary node sampling = ALND
  - Level I-III = ALND
  - SLNB + radiation = SLNB
- SLNB + completion ALND = SLNB

ALMANAC	Lymphede	ema at 12 months
	SLNB	ALND
Self none	95%	87%
Self mild	4%	11%
Self mod/severe	1%	2% p<.001
Change in arm volume (mean)	1.028	1.028 ns
BL Cancer Agency par company		

ALMA	NAC Senso month	ry Deficit at 12
	SLNB	ALND
Self reported	11%	31% p<.001
Median area of loss	59 cm <sup>2</sup>	$35 \text{ cm}^2 \text{ ns}$
Clinical opinion none	91%	69% p<.001
mild	8%	30% p<.001
Severe	1%	1% p<.001 for trend

	AC Shoulde onths (Mean	r Function at Change)
	SLNB	ALND
Flexion *	2.7 degrees	0.1 ns
Abduction *	2.5	1.9 ns
Ext Rotation	0.6	0.7 ns
Int Rotation	1.7	0.4 ns


# ALMANAC QOL


- Significantly different favouring sentinel node biopsy at all time points (1, 3, 6 and 12 months)
- ➢ Gradually improved over time for both groups
- More 'clinically meaningful' declines in ALND group
- SLNB group did not have more anxiety

## Conclusions:

- Loco-regional recurrence: SLND may have slightly higher recurrence rate 2- 3% vs 1 % for ALND
- Survival appears to be similar in prospective and meta analysis studies
- Complications are fewer but more significant than anticipated in patients undergoing SLNBs

#### BC Concer Agency





····Q····

Jul-Dec Jan-Jun Jul-Dec Jan-Jun Jul-Dec 1998 1999 1999 2000 2000

Surgeons "Vote With Their Feet" for Sentinel Node Biopsy for Breast Cancer Staging Tracy Hampton, PhD

JAMA. 2003;290:3053-3054.

#### Conclusions thus far:

- SLNBx is associated with a similar false negative rate as ALND
- SLNBx is probably not associated with statistically increased regional recurrence
- SLNBx is not associated with decreased overall survival
- SLNBx is associate with reduced QOL scores but still has morbidity

#### DC Cancer Agency

#### Kelowna Breast Consensus Panel

- SLNB will be offered as an alternative to AND to all patients with clinically node negative T I or II breast cancer.
- Before the patient decides between AND and SLNB, the physician must make a full and balanced presentation to the patient concerning the pros and cons of the two procedures.
- DC Concer Agency

#### Canadian Issues:

- Large geographic area that is not fully resourced
- Volumes of breast cancer cases and equipment availability will limit access
- SLNBx will not be available in every community in the Province
- Not every patient will want to travel from their community

#### BC Cancer Agency

# **Axillary Dissection Revisited**

- ➤Indications
- > What is a quality axillary dissection?

#### BC Concer Agency

### Indications

#### ➤ Staging

- ≻Clinical axillary disease
- ≻ Unable to do a sentinel node bx
- ▶ Unable to find the sentinel node
- >? Positive sentinel node bx

#### BE Cancer Agency

# Axillary Lymph Node Dissection: Quality Indicators

An inadequate axillary node dissection may result from a technical failure or pathologic understaging.

A small number of patients may develop an axillary recurrence due to disease biology/ resistance to therapies.

#### Axillary Dissection: adequate surgical resection

- Adequate anatomic dissection of level 1 & 2 lymph nodes
- Axillary lymph nodes: 3 levels defined by the pectoralis minor muscle
- > Level 1 : lateral or below the muscle
- > Level 2 : deep to the muscle
- Level 3 : medial to the muscle in the infraclavicular fossa

#### DC Concer Agency

## **Axillary Dissection**

- Level 1& 2 dissection 10 or more lymph nodes:
  - sufficient for staging in 97% of patients
  - Dissection is defined by specific anatomic planes


Danworth et al J Clin Oncol 1986;4:655-2


DC Concer Agency


#### Axillary Lymph Node Dissection: Level III?

#### ≻ Tominaga et al Br J Surg 2004

- 1209 pts with Stage II breast cancer randomized to Level I/II vs Level I/II/III axillary dissection
- 10 year OA survival 86.6% vs 85.7% (HR= 1.02, p=0.931)
- 10 year DFS 73.3% vs 77.8% (HR=0.94, p=0.666)









# Avoiding complications:


- Lymphedema: Do not raise thin flaps Do not strip the <u>axillary vein</u>
- Neuralgia: Sparing or dividing Intercoastalbrachial nerves does not seem to be associated with reduced neuralgia
- > Infection: Use iv antibiotics preoperatively
- **Hemorrhage:** Titanium clips
- ➢ Use Synoptic Reports


DC Concer Agency





























## **Consensus Statement**

Nodal staging is indicated in invasive breast cancer to determine prognosis, need for adjuvant therapy and to reduce risk of local/regional recurrence.

#### **Consensus Statement**

Sentinel lymph node biopsy causes less morbidity than a Level I and II axillary lymph node dissection.

#### DC Concer Agency

# DC Cancer Agency

#### **Consensus Statement**

Sentinel lymph node biopsy is an accurate staging alternative to axillary lymph node dissection for breast cancer.

#### BC Cancer Agency

#### **Consensus Statement**

Routine Level I and II axillary lymph node dissection can be eliminated for patients with histologic negative sentinel lymph nodes.

BC Concer Agency

#### Conclusions

- > ALND is indicated as a staging procedure when SLNBx is not available
- Surgeons managing breast cancer patients should use synoptic operative reports where available and should enrol their patients in quality outcome monitoring programs using national standards for reporting.

#### BL Cancer Agency

### Conclusions

- SLNB should be offered as an alternative to AND to all patients with clinically node negative stage I or II breast cancer.
- Before the patient decides between AND and SLNB, the physician must make a full and balanced presentation to the patient concerning the pros and cons of the two procedures.